Adults with type 2 diabetes are at high risk for long-term complications, including cardiovascular disease (CVD), kidney disease, and nerve damage. They face shorter life expectancies — by about 10 years — and increased rates of hospitalizations. Despite these odds, there is one thing patients can do to fight the statistics: take their medications consistently.
Researchers at the Diabetes Research Centre in Southmead, United Kingdom recently completed a meta-analysis of eight observational studies that demonstrated a link between medication adherence and risk for cardiovascular disease, all-cause mortality, and hospitalization in adults with type 2 diabetes. Published in the journal Diabetes Care, the meta-analysis collectively covered over 300,000 patients with an average medication adherence rate of 37.8 percent.
One study reporting on cardiovascular outcomes found a strong relationship between high medication adherence and lowered risk for CVD-related events. The other seven studies, which focused on mortality and hospitalization rates, found that high adherence led to significant benefits in both areas.
“Our findings should serve to reinforce to patients the importance of taking medications as prescribed in order to avoid premature death and preventable admissions to the hospital,” the authors wrote. They go on to urge health care professionals to continue reassessing adherence levels in clinical practice, taking action where it falls below 80 percent.
This meta-analysis confirms what AllazoHealth has known for many years: that good medication adherence is key to managing chronic diseases most effectively. This idea serves as the driving force behind our company, which strives to improve medication adherence through the use of predictive analytics and artificial intelligence. Our targeted interventions have reached hundreds of thousands of type 2 diabetes patients — empowering them to take control of their health in the long-term and sidestep these complications.